Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real‐world multicentre Italian study

Background Certolizumab, a pegylated tumour necrosis factor‐α inhibitor, reduced disease activity in randomized trials of patients with psoriasis and psoriatic arthritis. Real‐life data are missing. Objective To confirm the effectiveness and safety of certolizumab in patients with psoriasis and psor...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2020-12, Vol.34 (12), p.2839-2845
Main Authors: Dattola, A., Balato, A., Megna, M., Gisondi, P., Girolomoni, G., De Simone, C., Caldarola, G., Cama, E., Piaserico, S., Fargnoli, M.C., Fidanza, R., Parodi, A., Burlando, M., Offidani, A., Diotallevi, F., Potenza, C., Conti, A., Chiricozzi, A., Campione, E., Bianchi, L.
Format: Article
Language:English
Subjects:
Arthritis, Psoriatic - drug therapy
Humans
Italy
Middle Aged
Psoriasis - drug therapy
Quality of Life
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Certolizumab, a pegylated tumour necrosis factor‐α inhibitor, reduced disease activity in randomized trials of patients with psoriasis and psoriatic arthritis. Real‐life data are missing. Objective To confirm the effectiveness and safety of certolizumab in patients with psoriasis and psoriatic arthritis in routine clinical practice. Methods In this retrospective study involving 11 Italian sites, patients with psoriasis and psoriatic arthritis received subcutaneous certolizumab (400 mg loading dose at 0, 2 and 4 weeks, followed by 200 mg every 2 weeks) for up to 52 weeks. Primary outcomes included mean change from baseline in Psoriasis Area and Severity Index (PASI) and modified Nail Psoriasis Severity Index (mNAPSI) scores, and the proportion of patients achieving a 75%, 90% or 100% reduction in PASI score. Other endpoints included Disease Activity Score computed on 44 joints correlated with the erythrocyte sedimentation rate during the first hour (DAS44‐ESR), Tender Joint Count (TJC), Swollen Joint Count (SJC), pain [visual analogue scale (VAS) score], inflammatory markers and quality of life (QOL). Results In the study were enrolled 153 patients (mean age: 55 years). Certolizumab reduced the mean PASI score from baseline by 4.45, 6.30 and 7.58 at weeks 12, 24 and 52, respectively (P 
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.16606